Table 1.
Baseline characteristics of the study population by the AGR groups.
| AGR ≥ 1.2 | AGR < 1.2 | P-value | |
|---|---|---|---|
| Number of patients | 240 | 314 | – |
| Sex, men | 113 (47.08%) | 152 (48.41%) | 0.757 |
| Age (years) | 47.95 ± 14.07 | 56.71 ± 15.56 | < 0.001* |
| Body mass index (kg/m2) | 23.36 ± 3.86 | 23.5 ± 3.9 | 0.679 |
| Smoker | |||
| Never | 195 (81.25%) | 261 (83.12%) | 0.646 |
| Current | 7 (2.92%) | 5 (1.59%) | 0.443 |
| Former | 38 (15.83%) | 48 (15.29%) | 0.954 |
| Medications | |||
| ACE inhibitor/ARB | 142 (59.17%) | 201 (64.01%) | 0.244 |
| Erythropoiesis-stimulating agents | 227 (94.58%) | 290 (92.36%) | 0.298 |
| Vitamin D | 84 (35%) | 70 (22.29%) | 0.001* |
| Calcium channel blocker | 163 (67.92%) | 226 (71.97%) | 0.301 |
| Comorbid conditions | |||
| Hypertension | 203 (84.58%) | 268 (85.35%) | 0.802 |
| Diabetes mellitus | 46 (19.17%) | 140 (44.59%) | < 0.001* |
| Cardiovascular disease | 51 (21.25%) | 149 (47.45%) | < 0.001* |
| Hyperlipidemia | 46 (19.17%) | 96 (30.57%) | 0.002* |
| Status prior to PD | |||
| Predialysis CKD | 204 (85%) | 258 (82.17%) | 0.439 |
| Hemodialysis | 36 (15%) | 56 (17.83%) | 0.439 |
| Causes of CKD | |||
| chronic glomerulonephritis | 104 (43.33%) | 73 (23.25%) | < 0.001* |
| hypertension | 44 (18.33%) | 53 (16.88%) | 0.739 |
| Diabetes mellitus | 34 (14.17%) | 121 (38.54%) | < 0.001* |
| Others | 58 (24.17%) | 67 (21.34%) | 0.492 |
| Laboratory data | |||
| Albumin to globulin ratio | 1.4 (1.3, 1.6) | 1.0 (0.9, 1.1) | < 0.001* |
| Serum albumin (g/dL) | 3.8 (3.4, 4.1) | 3.0 (2.6, 3.3) | < 0.001* |
| Total protein (g/dL) | 6.4 (5.8, 6.9) | 6.1 (5.4, 6.7) | < 0.001* |
| Calcium (mg/dL) | 8.4 (8, 8.9) | 8.3 (7.9, 8.8) | 0.103 |
| Phosphorus (mg/dL) | 5.7 (5.0, 6.35) | 5.3 (4.4, 6.2) | < 0.001* |
| Cholesterol (mg/dL) | 185 (158, 213) | 184 (153, 225) | 0.676 |
| Triglyceride (mg/dL) | 115 (86, 157) | 123 (91, 172) | 0.145 |
| Creatinine (mg/dL) | 10.27 (8.61, 12.62) | 9 (7.51, 10.66) | < 0.001* |
| Ferritin (ng/mL) | 259.3 (131.1, 438) | 262.4 (131.3, 546.4) | 0.259 |
| GPT (U/L) | 15 (12, 22) | 17 (12, 24) | 0.11 |
| Hemoglobin (g/dL) | 8.6 (7.6, 9.4) | 8.8 (8, 9.5) | 0.015* |
| Intact PTH (pg/mL) | 381 (209.6, 606) | 307.7 (184, 485.08) | 0.004* |
| WBC count (×103/μL) | 6.7 (5.35, 8) | 7.49 (6.2, 9.2) | < 0.001* |
| PD-related parameters | |||
| D/P creatinine at 4 h | 0.66 (0.59, 0.73) | 0.69 (0.6, 0.78) | 0.002* |
| 24-h urine volume (L) | 1.05 (0.63, 1.41) | 0.73 (0.42, 1.15) | < 0.001* |
| Weekly total Kt/V urea | 2.12 (1.84, 2.4) | 1.95 (1.64, 2.26) | < 0.001* |
| nPNA (g/kg/day) | 1.11 (0.88, 1.29) | 1.01 (0.8, 1.17) | < 0.001* |
| Residual renal function (mL/min/1.73 m2) | 3.01 (2.33, 3.98) | 2.89 (1.87, 3.82) | 0.05* |
Values are expressed as mean ± SD, median and interquartile range, or number (percentage).
AGR, albumin–globulin ratio; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; GPT, glutamic-pyruvic transaminase; WBC, white blood cell; PTH, parathyroid hormone; D/P creatinine, dialysate-to-plasma creatinine ratio; nPNA, normalized protein nitrogen appearance; PD, peritoneal dialysis.
*p-value < 0.05.